-+ 0.00%
-+ 0.00%
-+ 0.00%

Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions?

Simply Wall St·02/05/2026 20:28:51
Listen to the news
  • AbCellera Biologics recently highlighted its transition from a service-focused antibody discovery platform to a clinical-stage biotech, with proprietary candidates ABCL635 and ABCL575 now in Phase 1 trials and more than 100 partnered programs contributing potential royalties.
  • This shift toward owning drug assets, alongside a broad royalty portfolio that includes 18 clinical programs, marks a meaningful change in how AbCellera may create and capture value within biopharma.
  • We’ll now examine how AbCellera’s move into clinical development with ABCL635 and ABCL575 could reshape the company’s broader investment narrative.

We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is AbCellera Biologics' Investment Narrative?

For AbCellera, the core belief as a shareholder is that its antibody discovery engine can translate into valuable drug assets and, over time, a portfolio of royalty streams. The latest update on ABCL635 moving into the Phase 2 portion of its Phase 1/2 trial, alongside continued progress on ABCL575, reinforces that the near term story now rests much more on clinical catalysts than on service revenue. With shares down sharply in recent months despite forecasts for strong revenue growth and a deep partnered pipeline, the key short term swing factors are upcoming data readouts through 2026 and how much cash the company burns to get there. The main risk is that AbCellera remains loss-making while its expensive valuation leans heavily on unproven clinical and royalty optionality.

However, investors should recognize how dependent the story has become on a few early clinical programs. Despite retreating, AbCellera Biologics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

ABCL 1-Year Stock Price Chart
ABCL 1-Year Stock Price Chart
Nine fair value views from the Simply Wall St Community span roughly US$7 to US$16.8 per share, reflecting wide disagreement. When you set that against AbCellera’s ongoing losses and heavy reliance on upcoming ABCL635 and ABCL575 data, it underlines why many participants are cautious and why comparing several viewpoints before forming a conclusion can be helpful.

Explore 9 other fair value estimates on AbCellera Biologics - why the stock might be worth over 5x more than the current price!

Build Your Own AbCellera Biologics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your AbCellera Biologics research is our analysis highlighting 2 key rewards that could impact your investment decision.
  • Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.

No Opportunity In AbCellera Biologics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.